Cat. No.: HY-B0920

Tolazamide

(Synonyms: U-17835)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC₅₀ = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 1156-19-0
Formula: C₁₄H₂₁N₃O₃S
Molecular Weight:311.40

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Tolazamide Chemical Structure

CAS No.: 1156-19-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

In Vitro

Tolazamide (0.1 nM-1 mM) inhibits Diazoxide (HY-B1140)-evoked responses dose-dependently in SUR1-Kir6.2 transfected HEK293 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tolazamide (40-400 μg/mL, 2 h) attenuates gluconeogenesis with both doses in control rats and inhibits gluconeogenesis in the liver tissue of diabetic rats with high concentration^[4].
Tolazamide (40-400 μg/mL, 1.5 h) attenuates ketogenesis (nanomoles of palmitate converted per min/mg DNA) from 5.2 to 3.5 and 2.7 with 40 and 400 μg/mL, respectively in the liver tissue of diabetic rats ^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1156-19-0
Appearance Solid
Molecular Weight 311.40
Formula C₁₄H₂₁N₃O₃S
Color White to off-white
SMILES

O=S(C1=CC=C(C)C=C1)(NC(NN2CCCCCC2)=O)=O
Synonyms

U-17835
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576

Solvent & Solubility

In Vitro:

DMSO : ≥ 39 mg/mL (125.24 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2113 mL

16.0565 mL

32.1130 mL

5 mM

0.6423 mL

3.2113 mL

6.4226 mL

10 mM

0.3211 mL

1.6057 mL

3.2113 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Mustafa Karakaya, et al., (2015) Theoretical and experimental investigations on vibrational and structural properties of tolazamide, Journal of Molecular Structure, Volume 1095, Pages 87-95, ISSN 0022-2860.

[2]. Gopalakrishnan, M., et al., (2000). Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells. British journal of pharmacology, 129(7), 1323–1332. [Content Brief]

[3]. Kabadi U. M. (1985). Adjuvant therapy with tolazamide and insulin improves metabolic control in type I diabetes mellitus. Diabetes care, 8(5), 440–446. [Content Brief]

[4]. McCormick, K., et al., (1986). Effect of tolazamide on basal ketogenesis, glycogenesis, and gluconeogenesis in liver obtained from normal and diabetic rats. Endocrinology, 119(3), 1268–1273. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2113 mL	16.0565 mL	32.1130 mL	80.2826 mL
	5 mM	0.6423 mL	3.2113 mL	6.4226 mL	16.0565 mL
	10 mM	0.3211 mL	1.6057 mL	3.2113 mL	8.0283 mL
	15 mM	0.2141 mL	1.0704 mL	2.1409 mL	5.3522 mL
	20 mM	0.1606 mL	0.8028 mL	1.6057 mL	4.0141 mL
	25 mM	0.1285 mL	0.6423 mL	1.2845 mL	3.2113 mL
	30 mM	0.1070 mL	0.5352 mL	1.0704 mL	2.6761 mL
	40 mM	0.0803 mL	0.4014 mL	0.8028 mL	2.0071 mL
	50 mM	0.0642 mL	0.3211 mL	0.6423 mL	1.6057 mL
	60 mM	0.0535 mL	0.2676 mL	0.5352 mL	1.3380 mL
	80 mM	0.0401 mL	0.2007 mL	0.4014 mL	1.0035 mL
	100 mM	0.0321 mL	0.1606 mL	0.3211 mL	0.8028 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Tolazamide

Membrane Transporter/Ion Channel Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Endocrinology Compound Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Human Metabolite Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Tolazamide

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Tolazamide

Membrane Transporter/Ion Channel Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Endocrinology Compound Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Human Metabolite Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Tolazamide

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Tolazamide Related Classifications

Cat. No.: HY-B0920